Linked Life Data

14602246

Source:http://linkedlifedata.com/resource/pubmed/id/14602246

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2003-11-6
pubmed:abstractText
Lung cancer is a major cause of mortality and morbidity worldwide. Overall survival has only improved slightly despite advances in surgery, radiotherapy, and chemotherapy. Molecularly targeted agents are currently being studied in all treatment settings including that of chemoprevention, which is defined as the use of natural or synthetic agents to interrupt the process of carcinogenesis and to prevent or delay tumour occurrence. Lung cancer has become an increasingly difficult problem to treat with standard therapies and chemopreventive strategies have been developed. Progress in chemoprevention is reliant on the collaborative efforts of researchers in basic science and clinical settings who study the biology of lung cancer with the goal of uncovering new mechanisms of carcinogenesis. Small molecules which target specific receptors or mutations such as inhibitors of epidermal growth factor receptor or RAS will have an increasingly significant role as they are associated with more tolerable side-effects and may prove more effective. Development of a risk model with intermediate endpoints is essential for future chemoprevention studies.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1470-2045
pubmed:author
pubmed:issnType
Print
pubmed:volume
4
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
659-69
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
Chemoprevention of lung cancer.
pubmed:affiliation
Departement of Medicine, Institut Gustave Roussy, Villejuif, France. soria@igr.fr
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't